Mueller Judith E, Bessaud Maël, Huang Q Sue, Martinez Laura C, Barril Patricia A, Morel Viviane, Balanant Jean, Bocacao Judy, Hewitt Joanne, Gessner Brad D, Delpeyroux Francis, Nates Silvia V
Agence de Médecine Préventive, Paris, France.
Appl Environ Microbiol. 2009 Mar;75(5):1395-401. doi: 10.1128/AEM.02201-08. Epub 2009 Jan 5.
This study compares the presence of environmental poliovirus in two Argentinean populations using oral poliovirus vaccine (OPV) or inactivated poliovirus vaccine (IPV). From January 2003 to December 2005, Córdoba City used IPV in routine infant immunizations, with the exception of intermittent OPV use in August 2005. Between May 2005 and April 2006, we collected weekly wastewater samples in Córdoba City and the province's three major towns, which continued OPV use at all times. Wastewater samples were processed and analyzed for the presence of poliovirus according to WHO guidelines. During the months of IPV use in Córdoba City, the overall proportion of poliovirus-positive samples was 19%. During an intermittent switch from IPV to OPV, this proportion increased to 100% within 2 months. During the 3 months when IPV was reintroduced to replace OPV, a substantial proportion of samples (25%) remained positive for poliovirus. In the OPV-using sites, on average, 54% of samples were poliovirus positive. Seventy-seven percent of poliovirus isolates showed at least one mutation in the VP1-encoding sequence; the maximum genetic divergence from the Sabin strain was 0.7%. Several isolates showed mutations on attenuation markers in the VP1-encoding sequence. The frequency or type of virus mutation did not differ between periods of IPV and OPV use or by virus serotypes. This study indicates that the sustained transmission of OPV viruses was limited during IPV use in a middle-income country with a temperate climate. The continued importation of poliovirus and genetic instability of vaccine strains even in the absence of sustained circulation suggest that high poliovirus vaccine coverage has to be maintained for all countries until the risk of reintroduction of either wild or vaccine-derived poliovirus is close to zero worldwide.
本研究比较了在阿根廷的两个人群中,使用口服脊髓灰质炎疫苗(OPV)或灭活脊髓灰质炎疫苗(IPV)后环境中脊髓灰质炎病毒的存在情况。2003年1月至2005年12月,科尔多瓦市在常规婴儿免疫接种中使用IPV,但2005年8月有间歇性OPV使用情况。2005年5月至2006年4月,我们在科尔多瓦市以及该省三个一直使用OPV的主要城镇每周收集废水样本。根据世界卫生组织指南对废水样本进行处理和分析,以检测脊髓灰质炎病毒的存在情况。在科尔多瓦市使用IPV的月份中,脊髓灰质炎病毒阳性样本的总体比例为19%。在从IPV间歇性转换为OPV期间,这一比例在2个月内增至100%。在重新引入IPV以取代OPV的3个月期间,相当比例的样本(25%)仍呈脊髓灰质炎病毒阳性。在使用OPV的地点,平均54%的样本呈脊髓灰质炎病毒阳性。77%的脊髓灰质炎病毒分离株在编码VP1的序列中显示至少一个突变;与萨宾株的最大遗传差异为0.7%。一些分离株在编码VP1的序列中的减毒标记上显示突变。IPV和OPV使用期间或不同病毒血清型之间,病毒突变的频率或类型没有差异。本研究表明,在一个气候温和的中等收入国家,使用IPV期间OPV病毒的持续传播受到限制。即使在没有持续传播的情况下,脊髓灰质炎病毒的持续输入和疫苗株的基因不稳定性表明,所有国家都必须维持高脊髓灰质炎疫苗接种覆盖率,直到野生或疫苗衍生脊髓灰质炎病毒重新引入的风险在全球范围内接近零。